Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New technique shields healthy liver during cancer radiation

NCT ID NCT06229080

Disease control Sponsor: Next Biomedical Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a method to protect healthy liver tissue during Yttrium-90 radioembolization, a radiation treatment for liver cancer. Doctors injected short-acting gelatin particles into arteries supplying non-cancerous liver areas to temporarily block blood flow. The goal was to reduce radiation damage to healthy tissue. Twenty adults with primary or metastatic liver cancer participated.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
gelatin sponge particles (NexGel)
What this could lead to
If successful, this technique could help preserve healthy liver function during radiation treatment for liver cancer, potentially reducing side effects.
What could go wrong
This is a small, early-stage study with only 20 participants and no control group. The approach may not improve outcomes or could cause unexpected complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

Mar 2023

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults aged 19 years or older 2. Patients diagnosed with primary or metastatic liver cancer based on histological and/or radiological findings 3. Patients determined, following medical, surgical, or multidisciplinary evaluation, to be best treated by radioembolization 4. Patients with no history of local treatments (e.g., ablation, chemoembolization) to the same hepatic lobe within the past year 5. Child-Pugh class A 6. Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower 7. Patients whose treatment area, as determined by planning angiography, includes at least two liver segments 8. Patients for whom normal liver tissue constitutes 50% or more of the treatment volume Exclusion Criteria: 1. Liver cancer with vascular invasion 2. For primary liver cancer, patients who have been diagnosed with a malignancy other than the primary liver cancer within 2 years prior to study enrollment 3. Patients who have undergone biliary-enteric anastomosis 4. Patients with an estimated lung dose of 30 Gy or higher on pre-procedure 99mTc-MAA imaging 5. Patients with a known contraindication to gelatin use

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Liver cancer (primary and metastatic) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

liver cancer Liver Neoplasms Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver cancer (primary and metastatic)

Contacts and locations

Locations

  • Seoul National University Hospital

    Seoul, 03080, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.